Windtree Therapeutics
WINT
WINT was delisted on the 20th of August, 2025.
4 hedge funds and large institutions have $1.88M invested in Windtree Therapeutics in 2020 Q2 according to their latest regulatory filings, with 4 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0% more ownership
Funds ownership: 0% → 0% (+0%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KC
Kepos Capital
New York
|
+$634K |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
+$317K |
| 3 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$317K |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$317K |
Top Sellers
WINT Hedge Fund Activity: Q2 2020 in Review
4 of the 4,888 institutional investors tracked by Wall St. Rank reported a position in Windtree Therapeutics (WINT) for Q2 2020, worth a combined $1.88M.
Buyers outnumbered sellers: 4 funds opened new WINT positions and 0 closed out — a net gain of 4 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Kepos Capital, opening a new position worth an estimated $634K.
- 4 institutional investors held Windtree Therapeutics (WINT) as of Q2 2020, up from 0 in Q1 2020.
- Funds reported $1.88M of Windtree Therapeutics stock for Q2 2020.
- 4 funds opened new Windtree Therapeutics positions in Q2 2020 and 0 closed out, a net change of +4 holders.
- The largest Windtree Therapeutics buyer in Q2 2020 was Kepos Capital, an estimated $634K added.
Based on aggregated 13F filings for Q2 2020.